Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by Donniebrasco57on Jan 08, 2020 9:01am
36 Views
Post# 30529723

RE:RE:DEAL COMING ! - SHORTS DISTRESSED !

RE:RE:DEAL COMING ! - SHORTS DISTRESSED !
Looking4Doubles wrote:
Looking4Doubles wrote: For 9 months the SHORTS / Bashers have claimed all kinds of things which have NEVER materialized. 

HOWEVER, . . . instead of these doomsday comments, we have seen the following:

1.) GREAT phase 2 test results
2.) MULTIPLE, UNSOLICITED, . . inquiries for the GVHD drug
3.) ADDITIONAL PATENTS have been secured covering the use of CBD in the treatment of GVHD
4.) The company announced the due dates of promissary notes owed to Talent could be extended to March 2020  IF a "TERM SHEET" was completed " for the license or disposition of the Company’s GVHD program or the sale or merger of the Company by December 15, 2019"
5.) An announcement was made that the promissary notes have been exteneded to March PER A PRIOR AGREEMENT WITH TALENT.  (HINT , HINT ! ! ! !) &

6.) Our resident SHORTS / Bashers are now PANICKING ! !  (Hint, Hint ! !)

I GUESS THEY WERE WRONG ! !  ha ha ha





SOMEONE CAN'T HANDLE THE TRUTH ! ! Yes, that's why they are posting 24/7 to scare people into selling their shares!!!
Bullboard Posts